Core reading: The eighth batch of national organized drug centralized procurement resulted in the proposed selection results, with 39 drugs successfully purchased, and the average price reduction of the proposed selected drugs was 56%. For the first time, it was included in heparin products, the "one main and two standby" supply mode, and multiple enterprises selected from the same variety... In 2023, the first national organization of drug centralized procurement, many highlights received much attention. The eighth batch of national organized drug centralized procurement ended on March 29 in Lingshui, Hainan, and a result of the proposed winning selection was obtained: 39 drugs were successfully purchased, with an average price reduction of 56% for the proposed winning drugs. Based on the agreed procurement volume, it is estimated that 16.7 billion yuan can be saved annually. So far, the National Health Insurance Bureau has organized eight batches of centralized procurement with a total of 333 types of drugs successfully purchased. Most of the varieties are used for common clinical diseases. For the first time, heparin products have been included. According to the "Notice on Improving the Centralized Procurement and Price Management of Medicines in 2023" previously issued by the National Health Insurance Administration, the coverage of centralized drug procurement will continue to expand. By the end of 2023, the cumulative number of national and provincial centralized drug procurement products in each province will reach 450. Among them, there should be 130 kinds of drugs collected at the provincial level, and chemical drugs, traditional Chinese patent medicines and simple preparations, and biological drugs should be covered. This national drug collection involves 366 products from 251 enterprises participating in bidding, covering drugs for common and chronic diseases such as anti infection, cardiovascular and cerebrovascular diseases, anti allergy, and mental diseases. According to Jiang Changsong, Assistant Dean of the National Medical Insurance Research Institute and Director of the Price Bidding and Procurement Office, most of the varieties collected this time are drugs for common clinical diseases. "Among them, there are some representative varieties, such as hypertension drugs, anticoagulant heparin drugs, oseltamivir for treating influenza A, and anti infective drugs that account for 40% of the total number of varieties." The focus of centralized procurement is how much the price has decreased. In this centralized purchase, the average price of the selected drugs will be reduced by 56%, which is 8 percentage points higher than the seventh batch of centralized purchase. Among them, the closely watched oseltamivir phosphate dry suspension for the treatment of influenza A has an average price reduction of 83%, while the commonly used antihypertensive drug amlodipine and atorvastatin calcium tablets have a price reduction of 48%. In addition, the price of a single dose of Atoxiban injection for the treatment of premature delivery exceeded 1000 yuan before the centralized purchase, and this centralized purchase decreased to an average of 240 yuan per dose, a decrease of 80%. The decrease in drug prices has reduced the burden of medication on the public. At the same time, this centralized purchase has effectively reduced the price of a batch of antibacterial drugs, removing the economic drivers of antimicrobial drug abuse, and also conducive to promoting rational clinical medication. Lu Yun, a professor at the School of International Medicine and Business at China Pharmaceutical University, said that the eighth batch of national drug centralized procurement continued the approach of encouraging medical institutions to report quantities in a reasonable manner in the seventh batch of centralized procurement, and as always, adhered to the goal of ensuring the implementation of the results of centralized procurement and benefiting the general public. This centralized purchase is the first time to include heparin products. This type of product is commonly used to prevent thrombosis or thrombotic diseases, and is used in treatment such as myocardial infarction and dialysis. Yue Xiaolin, Secretary of the Party Committee of Xuanwu Hospital of Capital Medical University, introduced that some heparin products are in short supply, and centralized procurement can provide sufficient market for production enterprises. Meanwhile, it can help hospitals identify manufacturers and suppliers, and stabilize the supply of short supply drugs. The design of centralized procurement rules is more refined to ensure a fair competition environment. Although the centralized procurement of drugs in the country has moved towards